



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

September 6, 2019

Manuel Litchman, M.D.  
President & CEO  
Mustang Bio, Inc.  
2 Gansevoort Street, 9th Floor  
New York, New York 10014

**Re: Mustang Bio, Inc.**  
**Preliminary Information Statement on Schedule 14C**  
**Filed August 16, 2019**  
**File No. 001-38191**

Dear Dr. Litchman:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Mark McElreath - Alston & Bird LLP